Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. - Wikidata - wikimedia - TriplyDB

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.

http://www.wikidata.org/entity/Q40305502

about

Profiling critical cancer gene mutations in clinical tumor samples Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.Is there something other than imatinib mesilate in therapeutic options for GIST?Clinical implications of the cancer genome Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors.Emerging drugs in chronic myelogenous leukaemia.Future options for imatinib mesilate-resistant tumors.Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.Recent advances in the treatment of gastrointestinal stromal tumors.Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor Nilotinib: a novel, selective tyrosine kinase inhibitor.Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.A potential role for nilotinib in KIT-mutated melanoma.Management of gastrointestinal stromal tumors.Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation?Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.

P2860

Q21562343-12C768AE-C4F8-4B70-88EF-8DFCC46F4F78 Q28483929-C81192CC-704F-4341-9C27-E0808F45EA95 Q33817421-94145577-F5AA-4D8C-A06E-86F158E94CFB Q34202396-7656906D-B091-46BF-A540-1F4CA466AAB8 Q34207379-B09D74AA-C43F-4191-AB4F-44534A6AA5C3 Q34488700-548AE8DA-96CF-4CEE-9744-3000852223F1 Q34499075-C148979C-9320-4737-A896-6821A9258700 Q34636081-7A5EAE3D-F347-4859-B466-6377B5DC47C1 Q35905878-8EE9C8D7-365B-4E3A-9DDD-7FD5B1CD86CC Q36125976-7FDEA39C-9F62-4A6B-BD12-81BD368DA8FC Q36180074-0F606AE8-F692-4700-83F4-18948A769D34 Q36573324-33C746B8-B0DF-42F9-A683-355942365C75 Q36634266-3BF76192-5149-4295-BE3A-DF36337E27E3 Q36964688-1C3EFC44-73CA-485B-8093-73376CD3430D Q37403226-0378062B-28F8-47BE-80EF-975CCC0AE815 Q37704347-C1D688FD-12E5-4857-B9CC-A16BA80C42C9 Q37813454-72F1D2E0-A2EB-4FC7-9AFE-DBF0803B2A8D Q37855073-5E206F9D-73C9-4266-9723-35975F17B533 Q37954207-5D819233-01D4-4F32-B023-775CC74D56ED Q38002439-1643F6B8-46E8-4F1C-9462-4FDDEC8BCC8D Q38081983-99FA538E-27F8-449E-9273-862D0CAB63CC Q38120079-2D8DEB07-8D37-485E-ACBB-23B6780AB0C4 Q38268165-115FEA43-7B48-4015-94BC-5C9AE8C72AF7 Q39688974-0AD8A044-086D-46FE-9ED0-1B935ECA900D Q39808264-EC02BADB-E19E-4825-9B5C-D39706309F0B Q40211560-919C8287-04D3-44C7-B201-6A5A8853A787 Q54599564-A4E7137B-E057-4D14-95D4-D79084FBB2DE Q54641441-2D96FB7B-FDAA-41F2-BE5B-6983B580A868

P2860

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.

http://www.wikidata.org/entity/Q40305502

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Cellular uptake of the tyrosin ...... inal stromal tumor cell lines.

@en

type

label

Cellular uptake of the tyrosin ...... inal stromal tumor cell lines.

@en

prefLabel

Cellular uptake of the tyrosin ...... inal stromal tumor cell lines.

@en

P1433

Q40305502-88F3A96C-A7E7-47E0-A991-674661DBBFF7

P1476

Q40305502-7B0A1CA9-E6EC-4414-89CA-AEAAA8D05AD2

P2093

Q40305502-1DD7B7C1-E755-476C-AA42-61E83E7D755B

Q40305502-21A6FAD5-8029-4009-BB5C-4C17E0AB90E3

Q40305502-41388397-7C2B-4745-9282-465F73DB4BA0

Q40305502-67F83729-8867-4172-9AE0-65B589DF0DB3

Q40305502-CD215C68-DDB1-4A40-803B-E46AA1A39BEA

Q40305502-DEFCD510-DAE7-42E0-BAC9-707882DC5EE6

P2860

Q40305502-0D04C86F-1161-46BA-A3AB-59B90EDE3A22

Q40305502-186786B0-B54C-4D13-BF1E-75A60BC17244

Q40305502-2C2F2A6F-F3FF-4D06-A5F1-DBD1379C3783

Q40305502-340DBF1C-BF6E-46E2-B6E9-EEC7DFBB4AAF

Q40305502-39B29683-0CE3-4486-AEDD-3597D499CE8C

Q40305502-86B0BE9C-647C-4BA9-933A-4F65476C379F

Q40305502-A37D4034-891A-42BA-B075-94F06BE5BA0D

P304

Q40305502-CFFAA193-AECF-494F-BB23-E5CA776384B9

P31

Q40305502-78BE0C67-8BC7-472C-BD57-09EE07761F67

P356

Q40305502-73664231-175E-4291-817C-CBD20A468A98

P433

Q40305502-988C4553-7566-4D5E-BB8E-D6DE1E39A5F5

P478

Q40305502-A25E06AB-BFBF-4E77-AE88-1A937A2D24BE

P50

Q40305502-4714A701-93CE-490F-8726-24030D61D2B8

Q40305502-C074A683-0ED2-453E-8A20-A28A66F230FA

P577

Q40305502-E61FF7AE-41EB-48DF-9D09-2D4E1D4FA5C9

P5875

Q40305502-1AF431E6-1CAF-4490-93E1-B9067B622E5A

P698

Q40305502-C7C73CC2-40D3-4985-B2BD-B9FE700B4B02

P356

P1433

P1476

Cellular uptake of the tyrosin ...... inal stromal tumor cell lines.

@en

P2093

Allan T van Oosterom

http://www.w3.org/2001/XMLSchema#string

Ernst de Bruijn

http://www.w3.org/2001/XMLSchema#string

Gert de Boeck

http://www.w3.org/2001/XMLSchema#string

Gunther Guetens

http://www.w3.org/2001/XMLSchema#string

Hans Prenen

http://www.w3.org/2001/XMLSchema#string

Paul Manley

http://www.w3.org/2001/XMLSchema#string

P2860

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

PDGFRA activating mutations in gastrointestinal stromal tumors.

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib.

P304

11-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000091943

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Schöffski

Maria Debiec-Rychter

P577

2006-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7244838

http://www.w3.org/2001/XMLSchema#string

P698

16534250

http://www.w3.org/2001/XMLSchema#string